Ricky Vaja1,2, Jeffrey Shi Kai Chan3,4, Plinio Ferreira1, Amer Harky5, Luke J Rogers6, Hime H Gashaw1, Nicholas S Kirkby1, Jane A Mitchell1. 1. Imperial College London, National Heart & Lung Institute, London, UK. 2. Royal Brompton Hospital, London, UK. 3. Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong. 4. Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong. 5. Liverpool Heart and Chest Hospital, Liverpool, UK. 6. University Hospitals Plymouth NHS Trust, Plymouth, UK.
Abstract
AIMS: In light of the recent safety concerns relating to NSAID use in COVID-19, we sought to evaluate cardiovascular and respiratory complications in patients taking NSAIDs during acute lower respiratory tract infections. METHODS: We carried out a systematic review of randomised controlled trials and observational studies. Studies of adult patients with short-term NSAID use during acute lower respiratory tract infections, including bacterial and viral infections, were included. Primary outcome was all-cause mortality. Secondary outcomes were cardiovascular, renal and respiratory complications. RESULTS: In total, eight studies including two randomised controlled trials, three retrospective and three prospective observational studies enrolling 44 140 patients were included. Five of the studies were in patients with pneumonia, two in patients with influenza, and one in a patient with acute bronchitis. Meta-analysis was not possible due to significant heterogeneity. There was a trend towards a reduction in mortality and an increase in pleuro-pulmonary complications. However, all studies exhibited high risks of bias, primarily due to lack of adjustment for confounding variables. Cardiovascular outcomes were not reported by any of the included studies. CONCLUSION: In this systematic review of NSAID use during acute lower respiratory tract infections in adults, we found that the existing evidence for mortality, pleuro-pulmonary complications and rates of mechanical ventilation or organ failure is of extremely poor quality, very low certainty and should be interpreted with caution. Mechanistic and clinical studies addressing the captioned subject are urgently needed, especially in relation to COVID-19.
AIMS: In light of the recent safety concerns relating to NSAID use in COVID-19, we sought to evaluate cardiovascular and respiratory complications in patients taking NSAIDs during acute lower respiratory tract infections. METHODS: We carried out a systematic review of randomised controlled trials and observational studies. Studies of adult patients with short-term NSAID use during acute lower respiratory tract infections, including bacterial and viral infections, were included. Primary outcome was all-cause mortality. Secondary outcomes were cardiovascular, renal and respiratory complications. RESULTS: In total, eight studies including two randomised controlled trials, three retrospective and three prospective observational studies enrolling 44 140 patients were included. Five of the studies were in patients with pneumonia, two in patients with influenza, and one in a patient with acute bronchitis. Meta-analysis was not possible due to significant heterogeneity. There was a trend towards a reduction in mortality and an increase in pleuro-pulmonary complications. However, all studies exhibited high risks of bias, primarily due to lack of adjustment for confounding variables. Cardiovascular outcomes were not reported by any of the included studies. CONCLUSION: In this systematic review of NSAID use during acute lower respiratory tract infections in adults, we found that the existing evidence for mortality, pleuro-pulmonary complications and rates of mechanical ventilation or organ failure is of extremely poor quality, very low certainty and should be interpreted with caution. Mechanistic and clinical studies addressing the captioned subject are urgently needed, especially in relation to COVID-19.
Authors: Justin T Reese; Ben Coleman; Lauren Chan; Hannah Blau; Tiffany J Callahan; Luca Cappelletti; Tommaso Fontana; Katie R Bradwell; Nomi L Harris; Elena Casiraghi; Giorgio Valentini; Guy Karlebach; Rachel Deer; Julie A McMurry; Melissa A Haendel; Christopher G Chute; Emily Pfaff; Richard Moffitt; Heidi Spratt; Jasvinder A Singh; Christopher J Mungall; Andrew E Williams; Peter N Robinson Journal: Virol J Date: 2022-05-15 Impact factor: 5.913
Authors: Mariana Alves; Marília Andreia Fernandes; Gülistan Bahat; Athanase Benetos; Hugo Clemente; Tomasz Grodzicki; Manuel Martínez-Sellés; Francesco Mattace-Raso; Chakravarthi Rajkumar; Andrea Ungar; Nikos Werner; Timo E Strandberg Journal: Eur Geriatr Med Date: 2021-05-25 Impact factor: 1.710
Authors: Kristian Kragholm; Thomas A Gerds; Emil Fosbøl; Mikkel Porsborg Andersen; Matthew Phelps; Jawad H Butt; Lauge Østergaard; Casper N Bang; Jannik Pallisgaard; Gunnar Gislason; Morten Schou; Lars Køber; Christian Torp-Pedersen Journal: Clin Transl Sci Date: 2020-10-21 Impact factor: 4.689
Authors: Nicholas Moore; Pauline Bosco-Levy; Nicolas Thurin; Patrick Blin; Cécile Droz-Perroteau Journal: Drug Saf Date: 2021-08-02 Impact factor: 5.606